The UK and US have concluded a major bilateral deal that will guarantee no levies on British drug products being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise spending on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial products will stay at zero for a timeframe of 36 months.
This deal comes after recent threats to dramatically increase duties on patented drug imports, with figures floated as high as double the cost.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and brings much-needed fairness to American-British medicine commerce," an announcement declared.
Trade Importance
Medicines constitute one of the UK's most significant export categories to the United States, which is clearly the primary buyer for major British pharmaceutical firms.
Statistics reveal that in the one-year period to the end of September, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure represented a significant portion of British export trade in that span.
"This agreement safeguards work, boosts investment and facilitates the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The pact involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
The deal comes amid a long-running row between the sector and the ministers over spending levels and NHS adoption.
The disagreement were heightened by assertions that American patients were paying a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while major funding commitments have been directed toward American operations.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the last ten years.
